APA

Ladetto M., Zallio F., Vallet S., Ricca I., Cuttica A., Caracciolo D., Corradini P., Astolfi M., Sametti S., Volpato F., Bondesan P., Vitolo U., Boccadoro M., Pileri A., Gianni A. M. & Tarella C. (20020122). Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. : Leukemia.

Chicago

Ladetto M, Zallio F, Vallet S, Ricca I, Cuttica A, Caracciolo D, Corradini P, Astolfi M, Sametti S, Volpato F, Bondesan P, Vitolo U, Boccadoro M, Pileri A, Gianni A M and Tarella C. 20020122. Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. : Leukemia.

Harvard

Ladetto M., Zallio F., Vallet S., Ricca I., Cuttica A., Caracciolo D., Corradini P., Astolfi M., Sametti S., Volpato F., Bondesan P., Vitolo U., Boccadoro M., Pileri A., Gianni A. M. and Tarella C. (20020122). Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. : Leukemia.

MLA

Ladetto M, Zallio F, Vallet S, Ricca I, Cuttica A, Caracciolo D, Corradini P, Astolfi M, Sametti S, Volpato F, Bondesan P, Vitolo U, Boccadoro M, Pileri A, Gianni A M and Tarella C. Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. : Leukemia. 20020122.